Biosensors

Biosensors: CIMB maintains Add with $1.19 TP. Note that share price volatility and enlarged trading volume of late have caught the attention of many investors. It is now harder for earnings to make any meaningful impact in the next two quarters and its bombed-out valuation and change in ownership suggest that the stock is no longer well owned. Think that the new shareholder, CITIC, could seek to enhance its investment value through more active participation, potentially even taking the company private. House keep EPS estimates and SOP-based target price. Also keep contrarian Add rating, which hinges on the instant success of product launches, regulatory approvals and M&A accretion.